February 2014 Issue of MMM
FEBRUARY 2014 issue
Gaming does not trivialize the patient's experience of a chronic disease
Click the above link to access the complete Digital Edition of the January 2014 issue, with all text, charts and pictures.
Pharma has reduced the burden of disease. It can develop a condition-specific app. But getting people to take their medications as prescribed? That's another matter. ...
As the Affordable Care Act rolls out, the behaviorists at MicroMass surveyed stakeholders about the impact on industry. Jessica Brueggeman sorts out the diverse views ...
The four newest luminaries honored by the Medical Advertising Hall of Fame built sterling reputations as they advanced their fields. Joshua Slatko looks back on ...
The MM&M Awards 2014 program is officially open for business. This is your chance to put your best work—and people —forward and get the recognition ...
Tactical ROIs aside, pharma must go beyond the detail to create longer-term value, say Croom Lawrence and Kent Groves, who offer a few tips for ...
Jorge Bartolome, SVP, US respiratory, GlaxoSmithKline
"New and improved" has entered this space. Alongside the existing compounds that are transforming the lives of patients with orphan ailments, a wave of incrementally ...
Pharma can be in the moment with customers as they interact with our information or products
Acetaminophen is a feel-good drug that is just too easy to overuse. We need to keep track of how much we take before we become ...
The ethical spotlight is once again pointed at Merck & Co., Inc. In December, Vanity Fair put a human face on the controversy swirling around ...
Pew Charitable Trust's proposed conflict of interest guidelines could mean even less face time for sales reps and less industry money for CME programs.
Two months after it was pulled from the US market, Iclusig is returning with a narrower approval.
News on Aegerion, Vivus, Merck and Gilead
Med Ed Report
The ACCME announced a public call for comment about its proposal to simplify the accreditation requirements and process, including revisiting a ban on commercial support ...
It looks like, for now, journal reprints and medical textbooks are reportable items under the Sunshine Act.
News on the Federation of State Medical Boards, Haymarket Medical Education, ACCME and the Audio-Digest Foundation
Elsevier is taking a hard-line posture against several different universities, asking them to take down scholarly research.
A month after UBM Canon closed the B2B magazine, marketing firm Outcomes LLC announced its return to twice-a-year publication.
News on Doximity, Hepatic Oncology and media group F1000
With physicians and patients engaging in more cross-platform behavior, marketers must be multi-screen to reach them. Yet only one-third of pharma sites are mobile-optimized. Can ...
The move to digitize a series of books it co-created with Disney for kids with type 1 diabetes was spurred by a meeting with the ...
CMS could provide more guidance for how to crack down on healthcare fraud, the OIG asserts in a report.
News on Merck, TGaS Advisors, Johnson & Johnson and AdhereTech
The six-year-old research group Stand Up To Cancer is featuring Samuel L. Jackson in its "In Play" campaign.
Belviq has launched a DTC campaign that positions weight-loss as being about health
Liberate Ideas and the American Academy of Physicians Assistants are rolling out the Liberate Health platform to give physician assistants more tools to communicate with ...
The regulator's proposed database could help identify adverse events.
The data and analytics giant is looking to launch an IPO. The company, which is the subject of an antitrust suit, said in its prospectus ...
Gregg Geider, who headed up high-profile accounts at Omnicom's Harrison & Star, has joined IPG's ICC Lowe Pace as managing director.
Endo signed Ogilvy PR to a one-year deal for comms support, following a selection process that reportedly lasted but a few weeks.
News on Havas, Fingerpaint Marketing, 3D Communications and Ogilvy
FDA's Warning Letter to Aegerion is a bureaucratic thumb in the eye to the US Court of Appeals
The US Supreme Court has declined, without comment, to hear a closely watched appeal by former InterMune CEO Scott Harkonen on whether someone can be ...
Public Citizen has written FDA asking it to stop making "misleading" statements about pharmacy compounding
These ads take aim at the aging male population. How well do they do at hitting their target?
Erik Hawkinson, Managing director, WCG
At Work With
Martin O'Brien, Partner, Rosetta
Promotions and hires for manufacturers and agencies
Success cures fear, and success is born out of focus and hard work
Skill Sets (advertising section)
What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.
A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.